GLP-1 Drug Adoption Boosts Hershey's Mint and Protein Sales

Hershey is experiencing an unexpected sales lift in its gum and mint categories, which CEO Kirk Tanner attributes to the growing adoption of GLP-1 agonists. The trend reflects a broader shift in consumer behavior as users of medications such as Ozempic, Wegovy, and Mounjaro alter their snacking habits. While not an official listed side effect, reports of dry mouth and halitosis among GLP-1 users have driven demand for breath-freshening products. Retail sales for Ice Breakers, the company's third-largest confection brand, grew by over 8% during the first quarter. Additionally, the company saw a 17% jump in protein bar sales, contributing to a total quarterly revenue increase of more than 10%. This pattern is not isolated to Hershey. Other premium confectioners, including Lindt & Spruengli and Magnum Ice Cream, have noted a 'premium treat substitution effect.' This phenomenon occurs as GLP-1 users eliminate low-quality snacking in favor of high-end treats, smaller portions, or functional snacks with higher protein content. Despite the revenue growth and the positive tailwinds from the functional snacking category, Hershey shares fell more than 2% in morning trading, suggesting that investors may be weighing these gains against broader market concerns or expectations.